Ultherapy
DeviceFocused ultrasound energy delivered below the surface of the skin.
Other names: Ulthera System Treatment
NCT Number: NCT02444169
A retrospective study to evaluate the Ulthera® System for its potential interaction with toxins and fillers. Up to 500 subjects will be enrolled.
Looking for future studies?
Notify Me25 year–70 year
All sexes
Observational
Aesthetic Plastic Surgical Institute, Laguna Beach, California, United States
This is a retrospective, multi-site study involving chart reviews of subjects who have received an Ultherapy treatment along with Radiesse®, Xeomin®, and/or Belotero® Balance within six months apart in the face and/or neck areas. Enrolled subjects will have received an Ultherapy treatment along with botulinum toxin A and/or filler treatment(s) within the last two years and with filler and toxin treatment occurring within 6 months before or after Ultherapy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Focused ultrasound energy delivered below the surface of the skin.
Other names: Ulthera System Treatment
An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
Other names: Xeomin
An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
Other names: Volumizing filler
An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
Other names: Dermal filler
Time frame: Within 6 months before or after Ultherapy
An assessment of adverse events through chart review will evaluate the safety of combination treatments of Ultherapy with toxins/fillers.
Ulthera, Inc
Industry
Retrospective Evaluation of Safety of Combination Treatment With the Ulthera® System and Xeomin, Belotero Balance, and Radiesse
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06724510
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases
Beijing, China
View Trial DetailsNCT06351358
Body Weight, Body Weight Changes
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06243744
Collagen Degeneration, Collagen Shrinkage
Bradenton, Florida, United States
View Trial DetailsNCT07255560
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases
Valencia, Spain
View Trial Details